China Shineway Pharmaceutical Group Limited announced that its Board of Directors will convene on 27 March 2026 at Suite 3109, 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong.
The agenda includes:
1. Approval for publication of the consolidated annual results for the financial year ended 31 December 2025.
2. Consideration of a dividend declaration for shareholders.
The notice was signed by Chairman Li Zhenjiang and dated 17 March 2026. The Board currently comprises three executive directors, one non-executive director, and three independent non-executive directors.